PDGFRB encodes platelet-derived growth factor receptor beta, a tyrosine kinase that plays essential roles in vascular development, fibrosis, and hematopoietic disorders. PDGFRB is critical for pericyte and smooth muscle cell recruitment to blood vessels and promotes neointimal hyperplasia through smooth muscle cell phenotypic modulation 12. The receptor is activated by PDGF ligands and signals through multiple pathways including PI3K/AKT and MAPK cascades. In pathological contexts, PDGFRB demonstrates both protective and harmful roles: it shows anti-fibrotic potential when inhibited in liver fibrosis models 3 and exhibits tumor-suppressive effects in osteosarcoma metastasis through PDGFD-PDGFRB signaling 4. However, PDGFRB also contributes to vascular disease progression, as PTPN14-mediated dephosphorylation at Y692 enhances PDGFRB activation and neointimal hyperplasia 2. Clinically, PDGFRB mutations are associated with familial myofibromatosis 5 and various hematopoietic malignancies, particularly eosinophilic myeloid disorders that respond to tyrosine kinase inhibitors like imatinib 67. These findings highlight PDGFRB as both a developmental regulator and potential therapeutic target.